|
|
Article: Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy.
- Article from:
- PR Newswire
- Article date:
- May 13, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New ToleroMune(R) Treatment Extends Circassia's Clinical-Stage Portfolio
OXFORD, England, May 13 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated a phase II clinical development programme for its ragweed allergy therapy. The treatment for allergic rhino-conjunctivitis caused by ragweed pollen is based on Circassia's ToleroMune(R) technology, which has previously achieved successful phase II results in patients with cat allergies. Ragweed is one of the leading causes of allergic reactions in North America, where allergies to its pollen are commonly referred to as 'hay fever'. Circassia ...
Related newspaper, magazine, and journal articles:
|
|
Article: Circassia Initiates Phase II Clinical Study With Novel ...
PR Newswire;
February 27, 2008 ;
700+ words
... ... allergy product range," said Steve Harris, Circassia's CEO. "This study is particularly ... information please visit http://www.circassia.co.uk/. CONTACT: Contacts: Steve Harris, CEO Circassia,Tel: +44-1865-784-574 ...
|
|